

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
6 October 2005 (06.10.2005)

PCT

(10) International Publication Number
WO 2005/092835 A1

(51) International Patent Classification⁷: **C07C 217/20**,
C07D 295/12, C07C 323/25, 55/10, 53/18, A61K 31/13,
31/40, A61P 25/00

Indiana 46038 (US). **JOHANSSON, Anette, Margareta**
[SE/US]; 6350 Brokenhurst Road, Indianapolis, Indiana
46220 (US). **SMITH, Sarah, Marie** [US/US]; 50 North
Sadlier Drive, Indianapolis, Indiana 46219 (US).

(21) International Application Number:
PCT/US2005/005226

(74) Agents: **GAYLO, Paul, J.** et al.; ELI LILLY AND COM-
PANY, P. O. Box 6288, Indianapolis, Indiana 46206-6288
(US).

(22) International Filing Date: 18 February 2005 (18.02.2005)

(25) Filing Language: English

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW.

(26) Publication Language: English

(30) Priority Data:
60/550,259 5 March 2004 (05.03.2004) US

(71) Applicant (*for all designated States except US*): **ELI
LILLY AND COMPANY** [US/US]; Lilly Corporate
Center, Indianapolis, Indiana 46285 (US).



(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BOULET, Serge,
Louis** [US/US]; 10813 Windemere Boulevard, Fishers,

[Continued on next page]

(54) Title: PHARMACEUTICAL COMPOUNDS



(57) Abstract: The present invention relates to inhibitors of serotonin and/or norepinephrine reuptake and specifically provides compounds of formula (I): wherein A is selected from -O- and -S-; X is selected from C₁-C₈ alkyl, C₂-C₈ alkenyl, and C₄-C₈ cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from phenyl, pyrrolidinyl, piperidinyl, morpholinyl, halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n where n is 0, 1 or 2, -CF₃, -CN and -CONH₂; Y is selected from (a), (b), (c), (d), (e), (f) where R₃, R₄ and R₅ are independently selected from hydrogen, halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano; R₆ and R₇ are independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano; R₈ is selected from chloro, bromo, iodo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano; R₁ and R₂ are each independently hydrogen or C₁-C₄ alkyl; or pharmaceutically acceptable salts thereof; or compositions thereof and methods of using the same.



European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ,

EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.